Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 630-635

  Cree, Ian A ^a   Kurbacher, Christian M ^b   Untch, Michael ^c   Sutherland, Lesley A ^d   Hunter, Elizabeth M ^d   Subedi, Andrea M C ^d   James, Elizabeth A ^d   Dewar, John A ^d   Preece, Paul E ^d   Andreotti, Peter E ^e   Bruckner, Howard W ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Atl Scientific Development Inc   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

ATP; Breast carcinoma; Chemiluminescence; Chemotherapy; Luciferase

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LUCIFERASE; PREDNISONE; VINCRISTINE;

ARTICLE; BREAST CANCER; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; PREDNISOLONE; PROGNOSIS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 10244261488     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00002     Document Type: Article

References (20)

1. Bellamy WT. Prediction of response to drug therapy of cancer A review of in vitro assays. Drugs 1992; 44: 690-708.
2. Bosanquet AG. In vitro drug sensitivity testing for the individual patient: an ideal adjunct to current methods of treatment choice. Clin Oncol R Coll Radiol 1993; 5: 195-7.
3. Lundin A, Hasenson M, Persson J, Pousette A. Estimation of biomass in growing cell lines by adenosine triphosphate assay. Methods Enzymol 1986; 133: 27-42.
4. Andreotti PE, Thornthwaite JT, Morse IS. ATP tumor chemosensitivity assay. In Stanley PE, Kricka LJ, eds. Bioluminescence and chemiluminescence: current status. Chichester: John Wiley 1991, 417-20.
5. Andreotti PE, Linder D, Hartmann DM, et al. ATP tumor chemosensitivity assay application for solid tumors and leukaemias. In: Szalay A, Kricka LJ, Stanley PE, eds. Chemiluminescence and bioluminescence: current status. Chichester: John Wiley 1993: 271-5.
6. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW TCA-100 tumor chemosensitivity assay: differences in sensitivity between cultured tumor cell lines and clinical studies J Bioluin Chemilum 1994; 9; 373-8.
7. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate ATP luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
8. Hunter EM, Sutherland LA, Cree LA, Dewar JA, Preece PE, Andreotti PE. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19: 242-9.
9. Hunter EM, Sutherland LA, Cree IA, et al. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anti-Cancer Drugs 1994; 5: 171-6.
10. Zeigler LD, Connelly JH, Frye D, Smith TL, Hortobagyi GN. Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer. Cancer 1991; 68: 628-33.
11. Petty RD, Sutherland LA, Hunter EM, Cree IA. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolum Chemilum 1995; 10: 29-34.
12. Cree IA, Pazzagli M, Mini E, et al. Methotrexate chemosensitivity by ATP luminescence in human leukaemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anti-Cancer Drugs 1995; 6: 398-404.
13. Untch M, Sevin BU, Perras JP, et al. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 1994; 53: 44-9.
14. Koechli OR, Avner BP, Sevin BU, et al. Application of the adenosine triphosphate cell viability assay in human breast cancer chemosensitivity testing: a report on the first results. J Surg Oncol 1993; 54: 119-25.
15. Untch M, Crohns C, Konecny G, et al. Correlation of in vitro tumor chemosensitivity assay with outcome in ovarian cancer patients given carboplatin and cyclophosphamide. Proc Am Soc Clin Oncol 1996; 15: 302 (abstr 841).
16. Sevin BU, Perras JP, Averette HE, Donato DM, Penalver M. Chemosensitivity testing in ovarian cancer. Cancer 1993; 71: 1613-20.
17. Kurbacher CM, Boese S, Mailman P, Krebs D. The ATP tumor chemosensitivity assay direct chemotherapy for recurrent ovarian cancer: first clinical results (abstr 09.07.04). Proc German Cancer Soc 1996: 79.
18. Stewart THM, Retsky MW, Tsai SCJ, Verma S. Dose response in the treatment of breast cancer. Lancet 1994; 343: 402-4.
19. Petty RD, Sutherland LA, Hunter EM, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 1994; 199: 264-70.
20. Kurbacher CM, Cree IA, Brenne U, et al. Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubiin evaluated by microplate ATP bioluminescence assay. Breast Cancer Res Treat 1996; in press.